LEFKOFSKY ERIC P sold $9.6M of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 166,250 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $57.48 ($55.38–$59.23, $9.56M total) across 10 trades on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LEFKOFSKY ERIC P
Published Jul 1, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
medium confidence
Mentioned
$TEM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The newest actionable element is the disclosed sale size (~166,250 shares; ~$9.56M) and the stated 10b5-1 pre-arranged plan, which frames the transaction as planned rather than opportunistic.

02

Market read

Newly filed insider-sale data can influence short-term sentiment, but 10b5-1 labeling typically limits interpretive weight.

03

What to watch

Traders may overreact to insider sales; the key is whether subsequent filings show sales outside the planned schedule or changes in total insider ownership trend.

Relevance 5/10Novelty 6/10Timing: after-hours/next-session read-through from a newly filed Form 4 (filed 2026-07-01)

Background

The article is an SEC Form 4 insider transaction disclosure for Tempus AI, Inc. (TEM) by CEO/Chairman Eric P. Lefkofsky, executed across multiple trades on 2026-06-29.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI CEO/Chairman Eric P. Lefkofsky sold ~$9.56M of TEM shares via a 10b5-1 plan on 2026-06-29 at $55.38–$59.23.

Expected impact

Likely limited, short-lived sentiment impact; watch for follow-through only if selling accelerates beyond planned cadence.

Evidence & confidence

The filing is primary-source and time-stamped, but it explicitly states a pre-arranged 10b5-1 plan, which typically dampens interpretation as new negative information.

Market effects

Minimal; this is company-specific insider transaction with no sector-wide catalyst.

Minimal; no broader macro or regional linkage in the filing details.

Minimal; no international deal/regulatory action described.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be routine liquidity management rather than a bearish signal.

Key entities

  • Tempus AI, Inc.

    Subject of the Form 4 insider sale; CEO/Chairman Eric P. Lefkofsky sold shares under a 10b5-1 plan.

  • LEFKOFSKY ERIC P

    CEO and Chairman; sold 166,250 shares indirectly on 2026-06-29 at $55.38–$59.23 (weighted avg $57.482).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.